PALO ALTO, Calif.--(BUSINESS WIRE)--Surf Bio, Inc., a biopharmaceutical company commercializing a novel drug stabilization platform, has received a $1.6 million grant from the Bill Melinda Gates Foundation. The grant will provide funding to evaluate the use of the company’s lead technology toward increasing the thermostability and deliverability of a monoclonal antibody in low- and middle-income countries. Surf Bio’s novel polymer technology enables the formulation of biologics at higher concentrations and in a more thermostable form than is currently available. Surf Bio's technology offers significant opportunities for improving the accessibility of advanced therapeutics in low- and middle-income countries by eliminating the requirement for refrigeration and enabling subcutaneous administration of biologics. “Surf Bio’s stabilization platform enables pharmaceutical formulations and delivery in resource-constrained settings that are not currently possible with today’s technologies,” said Bryan Mazlish, co-founder and CEO, Surf Bio. “We are thrilled to receive support from the Bill Melinda Gates Foundation to advance the use of our technology to enable greater access to biologics in low- and middle-income countries.”

Abbott partners with Bigfoot Biomedical to integrate Diabetes devices.